A5086954570- PARP inhibition in cancer therapy
- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Immune cells in cancer
- CRISPR and Genetic Engineering
- Immune Cell Function and Interaction
- RNA Interference and Gene Delivery
University Hospital of Zurich
2023-2024
University of Zurich
2023-2024
University of Geneva
2018
University of Lausanne
2018
Abstract Metastatic melanoma is either intrinsically resistant or rapidly acquires resistance to targeted therapy treatments, such as MAPK inhibitors (MAPKi). A leading cause of a dynamic transition cells from proliferative highly invasive state, phenomenon called phenotype switching. Mechanisms regulating switching represent potential targets for improving treatment patients with melanoma. Using drug screen targeting chromatin regulators in patient-derived three-dimensional MAPKi-resistant...
The combination of Programmed Cell Death 1 (PD-1) and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) blockade has dramatically improved the overall survival rate for malignant melanoma. Immune checkpoint blockers (ICBs) limit tumor's immune escape yet only approximately a third all tumors and, in most cases, limited amount time. Several approaches to overcome resistance ICBs are being investigated among which addition epigenetic drugs that expected act on both tumor cells. Guadecitabine,...
Abstract Background : The combination of Programmed Cell Death 1 (PD-1) and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) blockade has dramatically improved the overall survival rate for malignant melanoma. Immune checkpoint blockers (ICBs) limit tumor’s immune escape yet only approximately a third all tumors and, in most cases, limited amount time. Several approaches to overcome resistance ICBs are being investigated among which addition epigenetic drugs that expected act on both tumor cells....
<p>Contains supplementary tables, figures and materials methods.</p>
<p>LGX818 versus LGX818/TAL LFQ proteome analyses.</p>
<div>Abstract<p>Metastatic melanoma is either intrinsically resistant or rapidly acquires resistance to targeted therapy treatments, such as MAPK inhibitors (MAPKi). A leading cause of a dynamic transition cells from proliferative highly invasive state, phenomenon called phenotype switching. Mechanisms regulating switching represent potential targets for improving treatment patients with melanoma. Using drug screen targeting chromatin regulators in patient-derived...
<p>Contains supplementary tables, figures and materials methods.</p>
<p>LGX818 versus LGX818/TAL LFQ proteome analyses.</p>
<div>Abstract<p>Metastatic melanoma is either intrinsically resistant or rapidly acquires resistance to targeted therapy treatments, such as MAPK inhibitors (MAPKi). A leading cause of a dynamic transition cells from proliferative highly invasive state, phenomenon called phenotype switching. Mechanisms regulating switching represent potential targets for improving treatment patients with melanoma. Using drug screen targeting chromatin regulators in patient-derived...